Rechercher: „*“
90 Résultats
Frequently asked questions (FAQ)
On my country website of EfSM I find articles in my national language as well as in English. What’s it all about? Do I need to take out a subscription?…Access to EfSM Publication in different languages…All articles in EfSM are published in English and German. As long as there is no translation for your country, articles are shown in their English…Frequently asked questions (FAQ)
Meta-analysis and narrative review confirm the benefit of essential phospholipids in non-alcoholic …
Previous focus on treatment of comorbidities Significant benefit Meta-analysis confirms benefit of EPLs EPLs currently the most promising adjunctive treatment…Disclosures: Medical writing and publication funded by Sanofi. A recent meta-analysis [5] comprehensively investigated the state of knowledge concerning…Meta-analysis and narrative review confirm the benefit of essential phospholipids in non-alcoholic fatty liver disease
High compliance and treatment satisfaction with essential phospholipid treatment of patients with …
Treatment compliance correlates with positive effects High patient satisfaction High compliance and few treatment discontinuations Literature…Fig. 1. Changes in patient symptoms after 24 weeks (± 1 week) of treatment with EPL, categorised according to A) compliance, B) clinicians’ satisfaction…High compliance and treatment satisfaction with essential phospholipid treatment of patients with non-alcoholic fatty liver disease
Traitement de la douleur aiguë : comparaison de l’efficacité du lysinate d'ibuprofène et de …
Références bibliographiques …À ce jour, peu de données portent sur la comparaison directe entre l’ibuprofène et le lysinate d’ibuprofène Autres options pour accélérer le délai…L’ibuprofène est un anti-inflammatoire non stéroïdien prisé et très utilisé dans le traitement de la douleur aiguë légère à modérée. S’agissant d’un acide…Traitement de la douleur aiguë : comparaison de l’efficacité du lysinate d'ibuprofène et de l'ibuprofène
Bisacodyl: comprehensive findings direct effective and safe use in constipation
Bisacodyl has only local effects First indications of a positive effect on the gut microbiome Occasional constipation is a case for self-medication Significant…The review by Corsetti et al. [1] described the first results of studies that examined the influence of bisacodyl on the gut microbiome [5]. Compared to…Bisacodyl: comprehensive findings direct effective and safe use in constipation
Soulagement de la toux aiguë par un sirop contre la toux offrant une muco-protection
Références bibliographiques …En cas de rhume aigu, les symptômes de toux sont notamment déclenchés par une hypersensibilité neuronale du réflexe de la toux. Les rhinovirus, les bactéries…Soulagement de la toux aiguë par un sirop contre la toux offrant une muco-protection
Le macrogol – un traitement de la constipation conforme aux directives
Tableau: Le macrogol dans les directives internationales et nationales du traitement de la constipation [sélection] – Résumé Literature …Conclusions:…Les directives internationales s’accordent toutes : le macrogol apporte un soulagement efficace avec une bonne tolérance aux patients atteints de constipation…Le macrogol – un traitement de la constipation conforme aux directives
Author notes
Author notes
From virus deactivation in-vitro to clinical relevance: a glycerol and cod trypsin-containing mouth…
Literature…Virus deactivation – interesting approach in common cold treatment From in vitro to in vivo: Application via mouth spray – 6 times daily Conclusion…With the beginning of autumn, the common cold season starts – runny and stuffy nose, dry and chesty cough, sometimes accompanied by fever, headache or…From virus deactivation in-vitro to clinical relevance: a glycerol and cod trypsin-containing mouth spray in the common cold
Dexibuprofen – a portrait
Tab. 1. Pharmacokinetic properties of ibuprofen enantiomers (according to Evans et al. 2001 [3])…Efficacy and tolerability Conclusions Literature Summary Dexibuprofen: licensed as COX inhibitor in 23 countries Pharmacokinetics…Conflict of interest: The authors A. Gažová and J. Kyselovič declare no conflict of interest. E. Koscova is an employee of Sanofi. General properties…Dexibuprofen – a portrait